October 21, 2020
Dear FOXG1 Community,
As you may have learned, Taysha Gene Therapies is a new company that launched at the end of April focusing on developing gene therapies for central nervous system disorders.
Our Founder, President and CEO RA Session II became excited about the research program prior to joining Taysha after learning more about the high unmet medical needs associated with the disease. When RA founded Taysha, he recognized how certain technological gene therapy approaches available at our company, specifically those able to regulate re-expression of protein, could enable the team to identify a unique method of treating the cause of this disease in a regulated manner. It is now our pleasure to introduce the FOXG1 Community to Taysha Gene Therapies.
Taysha is a word in the Caddo Native American language meaning “ally” or “friend,” and when translated, also means “Texas.” Between our UT Southwestern collaboration and patient advocacy partnerships, we hope to be an ally to the rare disease community, including the FOXG1 community.
Our focus is gene therapy, which is a highly innovative approach to treating genetic diseases. We are working hand-in-hand with our collaborators at UT Southwestern collaborators, who are well-known gene therapy experts, medical experts in FOXG1 Syndrome, regulatory agencies and, importantly, patient groups every step of the way. We are truly embracing an integrated approach—one that will help get new medicines in the hands of physicians treating children affected by FOXG1 Syndrome in the most efficient, effective way possible.
We have a lot of work ahead of us but are encouraged by the strength of the FOXG1 Research Foundation that has been built to achieve this goal. By working together, our efforts will help bring gene therapy to the FOXG1 Community.
Warm regards,
The Taysha Team